Biotech in Review: Investment Capital for China Biopharma [View article]
here you go again missing the good news on china pharma receivables 1. reduced old receivables by more than 50% 2. sales up 60% while receivables up ONLY half that amount 3. bad debts not as bad as reservesd for originally
all good news--and WHY IS THIS A BIOTECH STOCK-NEXT MAYBE INCLUDED IN JUST TECH
-
here you go again missing the good news on china pharma receivables
May 05 10:45 am
|Rating:
0
0
All Comments by intelligence »Biotech in Review: Investment Capital for China Biopharma [View article]
1. reduced old receivables by more than 50%
2. sales up 60% while receivables up ONLY half that amount
3. bad debts not as bad as reservesd for originally
all good news--and WHY IS THIS A BIOTECH STOCK-NEXT MAYBE INCLUDED IN JUST TECH